Laman UtamaATYR • NASDAQ
add
aTyr Pharma Inc
$3.35
Selepas Waktu Dagangan:(1.19%)+0.040
$3.39
Tutup: 25 Apr, 6:57:32 PTG GMT-4 · USD · NASDAQ · Penafian
Tutup sebelumnya
$3.45
Julat hari
$3.29 - $3.47
Julat tahun
$1.42 - $4.66
Permodalan pasaran
297.68J USD
Bilangan Purata
1.42J
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Invezz
2 hari lalu
Amaran risiko: ‘kemelesetan sederhana’ boleh menjejaskan tahap S&P 500 kepada 3,700
0.74%
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 0.00 | — |
Perbelanjaan pengendalian | 3.59J | 12.11% |
Pendapatan bersih | -14.97J | -1.40% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | -0.18 | 28.00% |
EBITDA | -15.64J | 0.88% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 72.12J | -26.53% |
Jumlah aset | 96.83J | -19.75% |
Jumlah liabiliti | 27.00J | -10.55% |
Jumlah ekuiti | 69.83J | — |
Syer tertunggak | 88.86J | — |
Harga kepada buku | 4.16 | — |
Pulangan pada aset | -41.97% | — |
Pulangan pada modal | -48.88% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -14.97J | -1.40% |
Tunai daripada operasi | -13.13J | -18.71% |
Tunai daripada pelaburan | -6.08J | -134.15% |
Tunai daripada pembiayaan | 18.84J | 212.21% |
Perubahan bersih dalam tunai | -378.00K | -102.96% |
Aliran tunai bebas | -7.83J | -52.29% |
Perihal
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla. Wikipedia
Diasaskan
1 Jan 2005
Tapak web
Pekerja
61
